📋 REGENERON PHARMACEUTICALS, INC. (REGN) - Financial Results
Filing Date: 2025-10-28
Accepted: 2025-10-28 06:50:40
Event Type: Financial Results
Event Details:
Regeneron Pharmaceuticals Inc (REGN) Reports Q4 2025 Financial Results
Regeneron Pharmaceuticals Inc (REGN) announced its financial results for the period ending Q4 2025.
Key Financial Highlights:
Revenue: 3754
Net Income: 11.83
EPS: Not disclosed
Cash and equivalents: $0.88
In September 2025, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent in the European Union (EU) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older who remain symptomatic despite antihistamine treatment. The European Commission (EC) is expected to announce a final decision in the coming months.EYLEA HD (aflibercept) 8 mg
In October 2025, the Company was notified by Catalent Indiana, LLC (Catalent), the manufacturing filler in the EYLEA HD Biologics License Application (BLA), that they received an official action indicated (OAI) letter from the FDA citing unresolved issues related to a July 2025 FDA general site inspection (not specific to EYLEA HD). Yesterday, the FDA issued a Complete Response Letter (CRL) for the pre
filled syringe supplemental BLA (sBLA). The sole approvability issue cited in the CRL relates to unresolved inspection findings at Catalent. The Company is planning to submit by January 2026 an application to include a new pre
📋 REGENERON PHARMACEUTICALS, INC. (REGN) - Financial Results
Filing Date: 2025-10-28
Accepted: 2025-10-28 06:50:40
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: